World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

DeuteRx Celebrates Women’s History Month with Over a Decade of Pioneering Leadership in Drug Discovery

Cision PR Newswire by Cision PR Newswire
March 31, 2026
in Press Releases - Lifestyle
Reading Time: 6 mins read
0
Share on FacebookShare on Twitter

Chair, President, and CEO Sheila DeWitt, PhD, shares reflections and outlook on 15 Years of Drug Discovery and Four Landmark M&A Transactions

BOSTON, March 31, 2026 /PRNewswire/ — In honor of Women’s History Month, DeuteRx, LLC celebrates women and women-led companies driving leadership, growth and cultures of respect with long-term success. DeuteRx today issues a State of the Union update on the scientific contributions and executive leadership of Sheila DeWitt, PhD, Chair, President, and CEO, whose work has advanced and redefined pharmaceutical innovation for more than three decades.


DeuteRx, LLC (PRNewsfoto/DeuteRx LLC)

DeuteRx State of the Union Update

  • 2025–2026: Industry recognition for scientific and executive leadership
  • 2012–2025:  M&A transactions for metabolic, cancer, and psychiatric disorders
  • 2010–2012:  Innovation and validation of novel R&D platform

A Pioneer in Deuterated Drug Discovery

Dr. DeWitt invented Deuterium-Enabled Chiral Switching (DECS) in 2010, a novel strategy to stabilize interconverting stereoisomers in racemic drugs to facilitate development of the preferred stereoisomers and create improved therapeutics (ACS Med Chem 2020, 11, 1789). She cofounded Deuteria Pharmaceuticals to lead the initial proof-of-concept of DECS: the discovery of deuterium-stabilized S- lenalidomide (DP-053). Within two years, Deuteria and selected oncology programs were acquired by Celgene. The remaining non-oncology assets were transferred to a new venture, DeuteRx, LLC.

M&A Transactions and Key Scientific Discoveries

Using the DECS R&D strategy, Dr. DeWitt and her team successfully developed and monetized three additional drug candidate portfolios in:

  • 2025 for Psychiatric Disorders: DRX-184 (deuterium-stabilized S-bupropion) acquired by an undisclosed biopharmaceutical company. Key discovery: S-bupropion and S-related metabolites are predicted to drive the efficacy of bupropion.
  • 2022 for Cancer: SP-3164 (deuterium-stabilized S-avadomide) and related Targeted Protein Degraders (TPDs) acquired by Salarius Pharmaceuticals, Inc. Key discovery: S-enantiomers of cereblon-based TPD molecular glues drive efficacy, while R-enantiomers may promote tumor growth (Proc Natl Acad Sci USA, 2015, 112, E1471).
  • 2018for Metabolic Disorders: PXL065 (deuterium-stabilized R-pioglitazone), a Phase 1 drug candidate, and deuterated thiazolidinediones (TZDs) acquired by Poxel SA. Key discovery: the efficacy of TZDs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and other disorders is independent of PPARγ agonist activity and the associated side-effects of weight gain and edema (J Hepatol. 2023, 78, 914).

Industry Recognition & Awards for Innovation and Entrepreneurship

Inducted into the American Chemical Society (ACS) Medicinal Chemistry Hall of Fame in 2025, Dr. DeWitt was also honored with two prestigious ACS awards: the Kathryn C. Hach Award for Entrepreneurial Success and the Gertrude Elion Medicinal Chemistry Award. Both Kathryn and Gertrude were trailblazing female leaders who embraced challenges and broke new barriers.

“Women’s History Month is a time to reflect on the progress that has been made and the work that still lies ahead. I am proud of what the DeuteRx team has accomplished, not only with a commitment to advancing better medicines for patients, but in demonstrating that lean, focused, and value-driven science can compete at the highest levels. I hope our journey inspires and empowers the next generation of women in science, entrepreneurship, and leadership.” Sheila DeWitt, PhD, Chair, President & CEO, DeuteRx, LLC

Looking Ahead

Building on its proven drug discovery track, the DeuteRx team is advancing programs in spasticity, neuropathic pain, and rare dermatologic conditions. The company remains committed to applying the DECS strategy to create best-in-class therapeutics with clear clinical differentiation and strong commercial potential.

About DeuteRx, LLC

DeuteRx is a privately held biopharmaceutical company dedicated to developing differentiated new medicines with improved therapeutic profiles for patients. The company has pioneered DECS (deuterium-enabled chiral switching) to create differentiated NCEs with new composition of matter patent protection and the potential for an expedited and derisked development path. Success to date includes four asset sales for metabolic, cancer, and psychiatric disorders, remarkable discoveries with DECS, and >50 issued patents.

About Sheila DeWitt, PhD

Dr. Sheila DeWitt is an industry-recognized life sciences executive and serial entrepreneur with more than 35 years of leadership in pharmaceutical and biotechnology companies. She has led the start-up or turnaround of numerous biotechnology companies and business units, orchestrated transactions valued at billions of dollars, and managed global R&D organizations. Over the past 15 years, she has led the development and sale of four deuterated drug portfolios based on deuterium-enabled chiral switching (DECS). She earned her B.A. in Chemistry from Cornell University and her Ph.D. in Synthetic Organic Chemistry from Duke University.

For more information visit DeuteRx.com
DeuteRx Contact: info@deuterx.com  
Investors: mwallace@deuterx.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deuterx-celebrates-womens-history-month-with-over-a-decade-of-pioneering-leadership-in-drug-discovery-302727927.html

SOURCE DeuteRx LLC

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

    0 shares
    Share 0 Tweet 0
  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler